linjc16/ctgov huggingface dataset:
Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Procedure: IBZM-SPECT (bolus and constant infusion paradigm)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of schizophrenia (currently unmedicated) Subjects at risk for the development of schizophrenia (prodromal symptoms) Healthy subjects Written informed consent Exclusion Criteria: Neurological or severe somatic disorders Women during pregnancy or lactation Occupational exposition to radiation > 15mSv Medication known to interfere with IBZM Contraindications for the use of amphetamine challenge

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: IBZM-SPECT (bolus and constant infusion paradigm)|single IBZM-SPECT assessment at study inclusion|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dopamine receptor availability |  | cross-sectional | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IBZM-SPECT, Amphetamine Challenge, Schizophrenia, dopaminergic neurotransmission, Persons at risk for the development of schizophrenia, healthy subjects
Natural History Study of Retinitis Pigmentosa Type 11

Study Overview
=================
Brief Summary
-----------------
Observational study of patients with retinitis pigmentosa type 11

Detailed Description
-----------------
Natural history study with clinical examination every 6 months.

Official Title
-----------------
Natural History Study of Retinitis Pigmentosa Type 11

Conditions
-----------------
Retinitis Pigmentosa 11, Retinitis Pigmentosa

Intervention / Treatment
-----------------
* Diagnostic Test: Clinical examinations


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of retinitis pigmentosa caused by a disease-causing mutation involving the PRPF31 gene Or disease-causing mutation involving the PRPF31 gene without the clinical diagnosis of retinitis pigmentosa Exclusion Criteria: Under 18 years Other types of retinitis pigmentosa

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Clinical examinations|Clinical examinations|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression of disease | Retinal function measured by functional and structural testing | 24 mounths | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
RP, Retinitis, PRPF31
Clinical Usefulness of Virtual Ablation Guided Catheter Ablation of Atrial Fibrillation: Prospective Randomized Study

Study Overview
=================
Brief Summary
-----------------
Radiofrequency catheter ablation is highly effective in the treatment of patients with persistent atrial fibrillation. In order to decrease the recurrence rate after catheter ablation, the investigators propose to apply 'virtual' ablation on patient-specific atria by simulating 3D atrial computer model. The investigators will test with five different set of ablation methods and find successful methods for a specific patient. Then, this result will be compared to empirical catheter ablation result by randomly controlled trial.

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Procedure: Virtual ablation in based 3D CT of patient who diagnosed AF
* Procedure: conventional ablation based on physician's personal experience


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of AF patients who performed catheter ablation of atrial fibrillation due to uncontrolled pulse rate by anti-arrhythmic drug therapy. Exclusion Criteria: AF patients who have severe heart deformations or blood problems. The patients who had been performed catheter ablation of atrial ablation. The patients who missed out to recording of 3D CT, echo and electrocardiography.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: virtual simulation<br>This intervention group is to choose the best effective method operation to patients by simulating 3D atrial computer model which consider patient's heart size and shape. | Procedure: Virtual ablation in based 3D CT of patient who diagnosed AF<br> <br> |
| Active Comparator: conventional ablation<br>The other intervention group is to operate the atrial fibrillation by physician's personal experience, not by virtual simulation. | Procedure: conventional ablation based on physician's personal experience<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of hospitalization rate |  | 1, 3, 6, 12, 18 and 24 months after catheter ablation and every 6 months thereafter. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| occurence of cardiovascular disease |  | 6 months | 
| recurrence of AF |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atrial fibrillation, Virtual ablation, electrocardiography, electroanatomical mapping data
Effect of β-alanine Supplementation on Muscle Carnosine

Study Overview
=================
Brief Summary
-----------------
Carnosine is a natural acid buffering substance of muscle. The primary objective of this study is to test whether a nutritional supplement of beta-alanine enhances carnosine content in muscle.

Detailed Description
-----------------
Volunteers will be randomized to receiving 3 nutritional supplements. Two supplements contain beta-alanine at different doses, the third supplement is a placebo.

Official Title
-----------------
Effect of Two 8-week β-alanine Supplementation Protocols on Muscle Carnosine

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: placebo
* Dietary Supplement: beta-alanine
* Dietary Supplement: beta-alanine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stable health as evaluated by medical evaluation Body mass index higher than 18 kg/m2 Body mass index lower than 25 kg/m2, unless body fat is less than 20% Exclusion Criteria: intolerance to β-alanine, allergy to soy, fish and crustacean participation in another intervention study consumer of dietary supplement susceptible to contain beta-alanine determined to have very high baseline muscle carnosine concentration

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: beta-alanine 0<br> | Dietary Supplement: placebo<br>* daily<br>|
| Experimental: beta-alanine 1<br> | Dietary Supplement: beta-alanine<br>* daily<br>|
| Experimental: beta-alanine 2<br> | Dietary Supplement: beta-alanine<br>* daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| muscle carnosine concentration |  | 0 to 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
physical fitness, exercise, amino acid
Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University

Study Overview
=================
Brief Summary
-----------------
This is a prospective intervention study to assess the effectiveness of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection

Detailed Description
-----------------
This is a prospective intervention study to assess the short-term effectiveness of the first dose of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection by monitoring the antibodies (IgG, IgM and level of neutralizing antibodies) in sera of post-vaccinated persons. The study also will monitor the incidence of SARS-CoV-2 infection among vaccinees just before the first dose administration, 3 weeks after immunization, at the administration of the second dose, 14 days following the second dose and after 3 and 6 months.

Official Title
-----------------
Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Biological: Astrazeneca/Oxford Vaccine
* Biological: Sinopharm vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years old Candidate for receiving vaccination according to health care authorties prioritaizaton Exclusion Criteria: SARS-CoV-2 recovered cases <3 months Individuals who are currently infected with Sars-COV-2 and/or with respiratory symptoms with fever.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Astrazeneca/Oxford Vaccine|Viral non replicated vector vaccine contains the gene that encodes for the spike protein on the surface of the SARS-CoV-2 virus given Intramuscular injection in 2 doses 3 months apart|
|Biological: Sinopharm vaccine|Inactivated vaccine given intramuscular injection in 2 doses 3 weeks apart|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Short-term effectiveness | Assess the short-term effectiveness of the first dose of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection by monitoring the antibodies (IgG, IgM and level of neutralizing antibodies) in sera of postvaccinated persons three weeks after first dose | 21 days of the first dose of vaccine | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Egypt, Ain Shams University, Vaccine
Effect of Hypnosis on Dyspnea

Study Overview
=================
Brief Summary
-----------------
The purpose of this protocol is to test the effect of hypnosis on laboratory dyspnea.

Detailed Description
-----------------
This is a study of permissive suggestion in two laboratory models of dyspnea (work/effort, air hunger). Breathing discomfort rating induced by laboratory models of dyspnea will be assessed before, during and after hypnosis.

Official Title
-----------------
Effect of Hypnosis on Dyspnea

Conditions
-----------------
Healthy, Dyspnea

Intervention / Treatment
-----------------
* Behavioral: hypnosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy volunteers Exclusion Criteria: pregnancy ongoing pain respiratory disease high levels of depression, panic disorder, or other significant mental health problems not fluent in french

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: hypnosis, visual distraction<br>This is a crossover study in which each subject will be exposed to a 5 min phase of hypnotic suggestion and visual distraction. For hypnotic suggestion, subject will be invited to experience a pleasant memory . Indirect and permissive suggestion will be used. For visual distraction, subject will be watching the movie la marche des empereurs | Behavioral: hypnosis<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subject rating of Breathing Discomfort (affective component of dyspnea) | Subjects will rate breathing discomfort using a visual analog scale at baseline (pre-intervention), during the intervention (hypnosis/ visual distraction) and after intervention (recovery) while subject will be submitted to the laboratory model of dyspnea for 5 minutes (three runs of laboratory dyspnea (baseline, intervention and recovery). | continuous measurement for 5 minutes | 
| Subject rating of dyspnea intensity (sensory component of dyspnea) | Subjects will rate dyspnea intensity using a visual analog scale at baseline (pre-intervention), during the intervention (hypnosis/ visual distraction) and after intervention (recovery) while subject will be submitted to the laboratory model of dyspnea for 5 minutes (three runs of laboratory dyspnea (baseline, intervention and recovery). | continuous measurement for 5 minutes |
Pressurized PPV 23GA Vitrectomy in Complicated Diabetic Tractional Retinal Detachment

Study Overview
=================
Brief Summary
-----------------
To investigate the feasibility and advantages of using pressurized perfluorocarbon liquid (PCL) perfusion to remove vitreous during suction-cutting 23 GA vitrectomy using a dual, dynamic drive (3D)technology, in complicated retinal detachment surgeries.

Official Title
-----------------
Pressurized Perfluorocarbon Perfused 23 GA Vitrectomy in Complicated Diabetic Retinal Detachment

Conditions
-----------------
Retinal Detachment

Intervention / Treatment
-----------------
* Procedure: Vitrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Complicated retinal detachment with no more than 6months of evolution Exclusion Criteria: Retinal detachments of more than 6 months of evolution No light perception
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Vitrectomy|pressurized 23GA vitrectomy with a 3D system|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perfluorocarbon liquids consumption |  | two months |
Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV

Study Overview
=================
Brief Summary
-----------------
Safety and Efficacy of Paraplatin in combination with Taxol in patients of 70 years or older with epithelial ovary cancer F.I.G.O. stages III and IV.

Detailed Description
-----------------
The Main objective of this study is to evaluate the faisibility of chemotherapy with Paraplatin in combination with Taxol in patients of 70 years or older with epithelial ovary cancer F.I.G.O. stages III and IV and to determine principal predictive factors of this feasibility.

Official Title
-----------------
National, Phase II Study Designed to Evaluate the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III and IV. FAG-2

Conditions
-----------------
Ovarian Cancer

Intervention / Treatment
-----------------
* Drug: Paraplatin
* Drug: Paclitaxel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histological or cytological proven diagnosis of epithelial ovary cancer F.I.G.O stages III or IV (when only cytological proven diagnosis is available: malignant cells and pelvis tumoral mass and increased CA-125 must be diagnosed simultaneously) Patient aged > 70 years Neutrophil polynuclears > 1500/mm3 and Platelets > 100 000/mm3 No clinical icterus Life expectancy of at least 3 months Exclusion Criteria: Previous diagnosis of malignancy Previous chemotherapy treatment Previous radiotherapy Hypersensitivity to products containing Cremophore EL Hepatic values: bilirubine > 2*LSN, SGOT-SGPT > 2*LSN and/or Alkalin phosphatase > 3*LSN Myocardiopathy with arrhythmia

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Paraplatin|nan|
|Drug: Paclitaxel|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility of the combination Paraplatine + Taxol (at least 6 cures have been administered for a given patient and for the treated population, 50% feasibility) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Toxicity assessment |  |  | 
| Overall survival |  |  | 
| Progression-free survival |  |  | 
| Rate of response |  |  | 
| Quality of life |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Epithelial ovary cancer F.I.G.O. stages III or IV, 70 years or older
AbioCor Implantable Replacement Heart

Study Overview
=================
Brief Summary
-----------------
Abiocor is a post market approval study for an Implantable Replacement Heart. This post approval study is currently on hold.

Official Title
-----------------
AbioCor Implantable Replacement Heart

Conditions
-----------------
Severe Biventricular End Stage Heart Disease

Intervention / Treatment
-----------------
* Device: Abiocor Implantable Replacement Heart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients in severe biventricular end stage heart disease who are not cardiac transplant candidates and who are adults less than 75 years old, require multiple inotropic support, are not treatable by LVAD destination therapy, and are not weanable from biventricular support if on such support. Exclusion Criteria: Patients with other irreversible end organ dysfunctions that would compromise survival, having in clinical assessment a more than 30% chance of survival beyond 30 days, inadequate psychosocial support, or patients in whom fit is a problem, based on preoperative noninvasive anatomical assessment showing that the thoracic volume is unable to accommodate the device.

Ages Eligible for Study
-----------------
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Abiocor Implantable Replacement Heart|Replacement of heart|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
End stage heart disease
Facilitating Adolescent Self-Change for Alcohol Problems

Study Overview
=================
Brief Summary
-----------------
This present multi-site investigation compares a voluntary brief intervention for adolescent alcohol problems to an educational comparison condition. Measures are taken at intake and at 4 and 12 weeks post intake to determine effectiveness of the intervention to promote personal change efforts and arrest progression of alcohol problems. This study tests cognitive mechanisms of change and treatment characteristics and processes associated with youth self-regulation to reduce or stop hazardous drinking.

Official Title
-----------------
Facilitating Adolescent Self-Change for Alcohol Problems

Conditions
-----------------
Underage Drinking

Intervention / Treatment
-----------------
* Behavioral: Motivation interviewing based brief intervention
* Behavioral: Standard Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All 9th-12th graders at six schools from 3 sites across the country are eligible to participate, regardless of alcohol experience Exclusion Criteria: exclusion prior to 9th grade and after 12th grade

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Brief intervention<br>Motivational intervention based brief intervention | Behavioral: Motivation interviewing based brief intervention<br> <br> |
| Other: Standard intervention<br>Standard intervention condition | Behavioral: Standard Intervention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alcohol use and problems |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive mediators |  | one year |